ES2064435T3 - Aceleracion de la lisis de los coagulos. - Google Patents

Aceleracion de la lisis de los coagulos.

Info

Publication number
ES2064435T3
ES2064435T3 ES89303293T ES89303293T ES2064435T3 ES 2064435 T3 ES2064435 T3 ES 2064435T3 ES 89303293 T ES89303293 T ES 89303293T ES 89303293 T ES89303293 T ES 89303293T ES 2064435 T3 ES2064435 T3 ES 2064435T3
Authority
ES
Spain
Prior art keywords
clots
hapten
binding molecule
thrombolytic agent
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89303293T
Other languages
English (en)
Inventor
Guy L Reed
Gary Matsueda
Edgar Haber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2064435T3 publication Critical patent/ES2064435T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

LOS COAGULOS DE SANGRE Y EL INFARTO DE MIOCARDIO PUEDEN SER TRATADOS POR ADMINISTRACION DE UNA MOLECULA QUE SE UNE A HAPTENO, CAPAZ DE PREVENIR LA INHIBICION DE PLASMINA POR LA ALFA - 2 ANTIPLASMINA ENDOGENA. LA MOLECULA QUE SE UNE A HAPTENO PUEDE SER COADMINISTRADA CON UN AGENTE TROMBOLITICO CAPAZ DE DISOLVER LOS COAGULOS DE PLAQUETAS DE FIBRINA O DE INHIBIR SU FORMACION. ESTO CONDUCE A UNA DESTRUCCION AUMENTADA DE LOS COAGULOS A LA VEZ QUE SE DISMINUYE LA DEGRADACION DEL FIBRINOGENO Y SE PREVIENE LA REOCLUSION DE LA ARTERIA CORONARIA AFECTADA, INCLUSO EN AUSENCIA DE HEPARINA Y CUANDO LA CONCENTRACION DE AGENTE TROMBOLITICO ES MENOR QUE LA REQUERIDA POR OTRAS TERAPIAS POTENCIALES.
ES89303293T 1988-04-04 1989-04-04 Aceleracion de la lisis de los coagulos. Expired - Lifetime ES2064435T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17722288A 1988-04-04 1988-04-04

Publications (1)

Publication Number Publication Date
ES2064435T3 true ES2064435T3 (es) 1995-02-01

Family

ID=22647707

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89303293T Expired - Lifetime ES2064435T3 (es) 1988-04-04 1989-04-04 Aceleracion de la lisis de los coagulos.

Country Status (15)

Country Link
EP (1) EP0336693B1 (es)
JP (1) JP2871775B2 (es)
KR (1) KR100194113B1 (es)
AT (1) ATE114480T1 (es)
AU (1) AU628041B2 (es)
CA (1) CA1341377C (es)
DE (1) DE68919504T2 (es)
DK (1) DK174062B1 (es)
ES (1) ES2064435T3 (es)
FI (1) FI102812B (es)
GR (1) GR3015182T3 (es)
HU (1) HU207349B (es)
NO (1) NO301374B1 (es)
WO (1) WO1989009817A1 (es)
ZA (1) ZA892464B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
JPH02268694A (ja) * 1989-04-07 1990-11-02 Teijin Ltd 血栓溶解剤
EP0941345A2 (en) * 1996-09-20 1999-09-15 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US6524675B1 (en) 1999-05-13 2003-02-25 3M Innovative Properties Company Adhesive-back articles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735340B2 (ja) * 1985-05-23 1995-04-19 帝人株式会社 血栓溶解促進剤
ATE142502T1 (de) * 1986-05-15 1996-09-15 Univ Emory Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie

Also Published As

Publication number Publication date
GR3015182T3 (en) 1995-05-31
ATE114480T1 (de) 1994-12-15
CA1341377C (en) 2002-07-16
AU628041B2 (en) 1992-09-10
EP0336693B1 (en) 1994-11-30
NO904294L (no) 1990-12-04
FI904867A0 (fi) 1990-10-03
JPH03504717A (ja) 1991-10-17
AU3284589A (en) 1989-11-03
HUT56394A (en) 1991-08-28
ZA892464B (en) 1989-12-27
HU207349B (en) 1993-03-29
HU892304D0 (en) 1991-07-29
EP0336693A3 (en) 1990-03-21
NO301374B1 (no) 1997-10-20
FI102812B1 (fi) 1999-02-26
DK174062B1 (da) 2002-05-13
DE68919504D1 (de) 1995-01-12
KR900700129A (ko) 1990-08-11
DE68919504T2 (de) 1995-06-29
FI102812B (fi) 1999-02-26
DK240190A (da) 1990-10-04
KR100194113B1 (ko) 1999-06-15
JP2871775B2 (ja) 1999-03-17
EP0336693A2 (en) 1989-10-11
NO904294D0 (no) 1990-10-03
DK240190D0 (da) 1990-10-04
WO1989009817A1 (en) 1989-10-19

Similar Documents

Publication Publication Date Title
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
ES2064435T3 (es) Aceleracion de la lisis de los coagulos.
BR9708859A (pt) Composto uso do mesmo composição para inibir formação de trombo em sangue e processos para inibir trombina e formação de agregados de plaquetas sanguíneas e de trombo no sangue para tratar ou evitar tromboemolismo venoso e embolismo pulmonar trombose tromboembolismo cardiogênico acidente vascular cerebral trombose angina instável infartação miocárdica aterosclerose distúrbio cardaco isquêmico reoclus o restenose oclus o de enxertos de derivação de artéria coronária e doença cerebrovascular oclus
ATE250604T1 (de) Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
DK36991A (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
DK0519903T3 (da) Lægemiddel indeholdende aktiveret protein C
ES2076965T3 (es) Activadores del plasminogeno salivares del murcielago vampiro.
DK37789A (da) Antikoagulerende middel samt anvendelse heraf
ES2070116T3 (es) Peptidos que inhiben la union del factor von willebrand.
EP0348208A3 (en) Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
DK226889D0 (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
ATE84724T1 (de) Gewisse paf-antagonist/antihistamin-mischungen und verfahren.
DE68922859T2 (de) Trombolytischer wirkstoff mit modifikation der domäne der kringle.
VI PLATELET INHIBITORS IN ARTERIALTHROMBOSIS ANDATHEROCENESIS.
ATE191278T1 (de) Tetrahydroxychinon als eine aktivatorkomponente für den aktivierten partiellen thromboplastinzeit-test der blutgerinnung und als anzeiger von blutgerinnungsstörungen
NO308140B1 (no) Anvendelse av protrombinfragmenter
MX174250B (es) Composicion con actividad antiagregante de plaqueta util en terapias
Norman III. INHIBITORS OF THE FIBRINOLYTIC SYSTEM
TAYLOR et al. Prolonged Clot Lysis Time and Absence of Platelet γM-globulin in Patients with Thrombasthenia
von Kaulla In vitro inhibition of aggregation of human erythrocytes by synthetic fibrinolytic compounds
Shafer et al. Thrombolytic therapy. Current and potential uses.
ATE81589T1 (de) Verwendung von folinsaeurederivaten als plaettchenaggregationshemmstoffe.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 336693

Country of ref document: ES